Its my understanding that a voluntarily audit was completed and all finding being disproved. Head over to their website. They have a section allocated to the report.
I think this is a very compelling business to cover, great choice! (Disc: I own the stock).
What I'm still trying to figure out is if there's a high-ROIIC runway outside the "Testing" market, namely in the "Diagnostics" market where the company may deploy the majority of its future reinvesting capital. An InPracise interview has a quote (not behind a paywall) that says developing new diagnostics costs capex, but these new diagnostics become commoditized over time. This ROIIC will determine the stock's compounding potential.
p.s. There was some controversy around this stock last year (short report). I just mention this for completeness, not to open a discussion, and apologies if you've already mentioned it elsewhere.
I would like to assume management would not deploy capital if they where receiving a low return. They've stated investments must cross the company's hurdle rate which stands at 16% before taxes (Unable to locate source). The reinvestment of capital is quite diverse when you consider acquisitions, start ups and building out their IT solutions so I'm not too concerned on where this capital ends up.
I didn't mention the short report. If I've done my research correctly this seems to have been concluded after a voluntarily audit was completed and all finding being disproved.
What are your thoughts on MW? Seems detailed but the detail is above my paygrade
Its my understanding that a voluntarily audit was completed and all finding being disproved. Head over to their website. They have a section allocated to the report.
I think this is a very compelling business to cover, great choice! (Disc: I own the stock).
What I'm still trying to figure out is if there's a high-ROIIC runway outside the "Testing" market, namely in the "Diagnostics" market where the company may deploy the majority of its future reinvesting capital. An InPracise interview has a quote (not behind a paywall) that says developing new diagnostics costs capex, but these new diagnostics become commoditized over time. This ROIIC will determine the stock's compounding potential.
p.s. There was some controversy around this stock last year (short report). I just mention this for completeness, not to open a discussion, and apologies if you've already mentioned it elsewhere.
Appreciate the comment Frederik.
I would like to assume management would not deploy capital if they where receiving a low return. They've stated investments must cross the company's hurdle rate which stands at 16% before taxes (Unable to locate source). The reinvestment of capital is quite diverse when you consider acquisitions, start ups and building out their IT solutions so I'm not too concerned on where this capital ends up.
I didn't mention the short report. If I've done my research correctly this seems to have been concluded after a voluntarily audit was completed and all finding being disproved.
Didnt see it in the website but will circle back